TRIP6 enhances stemness property of breast cancer cells through activation of Wnt/β-catenin
Open Access
- 14 February 2020
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-11
Abstract
Background: The urgent problem in the treatment of breast cancer is the recurrence induced by breast cancer stem cells (CSCs). Understanding the role and molecular mechanism of specific molecules in breast cancer stem cells can provide a theoretical basis for better treatment. TRIP6 is an adapter protein which belongs to the zyxin family of LIM proteins and is important in regulating the functions of CSCs. The present study aims to investigate the effects and mechanism of TRIP6 in breast cancer. Methods: TRIP6 expression in breast cancer cells and tissues were detected by Real-Time PCR, western blot and immunohistochemistry (IHC). MTT assays, colony formation assays, Xenografted tumor model and mammosphere formation assays were performed to investigate the oncogenic functions of TRIP6 in the tumorigenic capability and the tumor-initiating cell-like phenotype of breast cancer cells in vitro and in vivo. Luciferase reporter, subcellular fractionation and immunofluorescence staining assays were performed to determine the underlying mechanism of TRIP6-mediated stemness of breast cancer cells. Results: TRIP6 expression was significantly upregulated in breast cancer, and was closely related to the clinicopathologic characteristics, poor overall survival (OS), relapse-free survival (RFS) and poor prognosis of breast cancer patients. Functional studies revealed that overexpression of TRIP6 significantly enhanced proliferative, tumorigenicity capability and the cancer stem cell-like properties of breast cancer in vitro and in vivo. On the contrary, silencing TRIP6 achieved the opposite results. Notably, we found that TRIP6 promoted Wnt/β-catenin signaling pathway in breast cancer to strengthen the tumor-initiating cell-like phenotype of breast cancer cells. Conclusions: This study indicates that TRIP6 plays an important role in maintaining the stem cell-like characteristics of breast cancer cells, supporting the significance of TRIP6 as a novel potential prognostic biomarker and therapeutic target for diagnosis and treatment of breast cancer.Keywords
Funding Information
- National Natural Science Foundation of China (81602141)
This publication has 32 references indexed in Scilit:
- The Adaptor Protein TRIP6 Antagonizes Fas-Induced Apoptosis but Promotes Its Effect on Cell MigrationMolecular and Cellular Biology, 2010
- Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor OutcomeThe American Journal of Pathology, 2010
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput ScreeningCell, 2009
- Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin SignalingPLOS Biology, 2009
- TRIP6, a novel molecular partner of the MAGI‐1 scaffolding molecule, promotes invasivenessThe FASEB Journal, 2008
- Restriction to Fos Family Members of Trip6-Dependent Coactivation and Glucocorticoid Receptor-Dependent Trans-Repression of Activator Protein-1Molecular Endocrinology, 2008
- Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and AngiogenesisJournal of Clinical Oncology, 2008
- Cancer stem cells – old concepts, new insightsCell Death & Differentiation, 2008
- Wnt/β-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell lineJournal of Cell Science, 2007
- Supervillin modulation of focal adhesions involving TRIP6/ZRP-1Journal of Cell Biology, 2006